Skip to main content
. 2016 Apr 4;34(15):1764–1771. doi: 10.1200/JCO.2015.64.5788

Fig 1.

Fig 1.

Mean observed pharmacokinetic (PK) profiles of LY2606368 after single- and multiple-dose administration at the maximum-tolerated dose of schedules (SCH) 1 and 2. (A) Mean PK profile of LY2606368 40 mg/m2 (SCH 1) on days 1 and 3 of cycle 1 and day 3 of cycle 2. (B) Mean PK profile of LY2606368 105 mg/m2 (SCH 2) on day 1 of cycles 1 and 2.